BioLineRx (BLRX) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts BLRX Hot Sheet
Join SI Premium – FREE
BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.01), $0.20 better than the analyst estimate of ($0.21).
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- Sprott Inc. (SII) Misses Q3 EPS by 11c
- Wayfair shares fall 3% in premarket trading despite Q3 revenue, earnings beat
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
